Article Text

Download PDFPDF
Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: an open-label, non-inferiority, randomized trial (ALICE trial)
  1. Glauco Baiocchi1,
  2. Carlos Eduardo Mattos Cunha Andrade2,
  3. Reitan Ribeiro3,
  4. Renato Moretti-Marques4,
  5. Audrey Tieko Tsunoda3,5,
  6. Vanessa Alvarenga-Bezerra4,
  7. Andre Lopes6,
  8. Ronaldo Lúcio Rangel Costa6,
  9. Lillian Yuri Kumagai1,
  10. Levon Badiglian-Filho1,
  11. Carlos Chaves Faloppa1,
  12. Henrique Mantoan1,
  13. Louise De Brot7,
  14. Ricardo Dos Reis2 and
  15. Bruna Tirapelli Goncalves1
  1. 1 Gynecologic Oncology, AC Camargo Cancer Center, São Paulo, Brazil
  2. 2 Gynecology Oncology, Barretos Cancer Hospital, Barretos, Brazil
  3. 3 Gynecologic Oncology, Erasto Gaertner Hospital, Curitiba, Brazil
  4. 4 Gynecologic Oncology, Hospital Israelita Albert Einstein, São Paulo, Brazil
  5. 5 PPGTS, Universidade Positivo, Curitiba, Brazil
  6. 6 Gynecology, São Camilo Oncologia, São Paulo, Brazil
  7. 7 Pathology, AC Camargo Cancer Center, São Paulo, Brazil
  1. Correspondence to Dr Glauco Baiocchi, Gynecologic Oncology, AC Camargo Cancer Center, São Paulo 01509-010, Brazil; glauco.baiocchi{at}accamargo.org.br

Abstract

Background Growing evidence suggest that sentinel lymph node (SLN) biopsy in endometrial cancer accurately detects lymph node metastasis. However, prospective randomized trials addressing the oncological outcomes of SLN biopsy in endometrial cancer without lymphadenectomy are lacking.

Primary Objectives The present study aims to confirm that SLN biopsy without systematic node dissection does not negatively impact oncological outcomes.

Study Hypothesis We hypothesized that there is no survival benefit in adding systematic lymphadenectomy to sentinel node mapping for endometrial cancer staging. Additionally, we aim to evaluate morbidity and impact in quality of life (QoL) after forgoing systematic lymphadenectomy.

Trial Design This is a collaborative, multicenter, open-label, non-inferiority, randomized trial. After total hysterectomy, bilateral salpingo-oophorectomy and SLN biopsy, patients will be randomized (1:1) into: (a) no further lymph node dissection or (b) systematic pelvic and para-aortic lymphadenectomy.

Major Inclusion and Exclusion Criteria Inclusion criteria are patients with high-grade histologies (endometrioid G3, serous, clear cell, and carcinosarcoma), endometrioid G1 or G2 with imaging concerning for myometrial invasion of ≥50% or cervical invasion, clinically suitable to undergo systematic lymphadenectomy.

Primary Endpoint(s) The primary objective is to compare 3-year disease-free survival and the secondary objectives are 5-year overall survival, morbidity, incidence of lower limb lymphedema, and QoL after SLN mapping ± systematic lymphadenectomy in high-intermediate and high-risk endometrial cancer.

Sample size 178 participants will be randomized in this study with an estimated date for completing accrual of December 2024 and presenting results in 2027.

Trial Registration Number NCT03366051.

  • endometrial neoplasms
  • sentinel lymph node
  • postoperative complications
  • quality of life (pro)/palliative care

Data availability statement

Data are available upon request.

Statistics from Altmetric.com

Footnotes

  • Twitter @glaucobaiocchi, @andrelopesMD

  • Contributors Study concept and design: GB, BTG. Data acquisition: GB, BTG. Manuscript preparation and editing: GB, BTG. Manuscript review: all authors. Author responsible for the overall content as the guarantor: GB.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.